The chronic heart failure (CHF) market is expected to grow significantly over the next 10 years across the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK). The CHF market has predominantly been saturated with generics, which has limited the market revenue; however, there are a growing number of late-stage pipeline therapies, which, combined with the rising disease prevalence, will be major drivers of market growth. 

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are beginning to alter the existing CHF treatment landscape, as seen in updates that have recently been made to treatment guidelines in the US, EU, and Japan, which now recommend the use of SGLT-2 inhibitors in the first line, in combination with drugs targeting the renin-angiotensin-aldosterone system, beta blockers, and mineralocorticoid receptor antagonists. 

This Datamonitor Healthcare report contains a Disease Analysis module.